Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Trial Comparing a Combination of Abraxane and Gemcitabine Versus Gemcitabine Alone as First Line Treatment in Locally Advanced Unresectable Pancreatic Cancer. GAP (Gemcitabine Abraxane Pancreas) Trial

NCT02043730 is registered in ClinicalTrials.gov with Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente as lead sponsor.

NCT NCT02043730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02043730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Trial Comparing a Combination of Abraxane and Gemcitabine Versus Gemcitabine Alone as First Line Treatment in Locally Advanced Unresectable Pancreatic Cancer. GAP (Gemcitabine Abraxane Pancreas) Trial
Lead sponsor
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2014
Completion date
January 14, 2019
Enrollment
124 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer stage ii